SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAGANELLI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.960
AS - Asia 8.116
EU - Europa 4.361
SA - Sud America 1.433
Continente sconosciuto - Info sul continente non disponibili 554
AF - Africa 193
OC - Oceania 19
Totale 29.636
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.601
SG - Singapore 3.383
CN - Cina 1.544
PL - Polonia 1.294
BR - Brasile 1.161
IT - Italia 851
VN - Vietnam 851
HK - Hong Kong 730
DE - Germania 388
BD - Bangladesh 375
TR - Turchia 362
GB - Regno Unito 342
UA - Ucraina 328
SE - Svezia 280
RU - Federazione Russa 215
FR - Francia 202
CA - Canada 171
IN - India 153
JP - Giappone 149
ID - Indonesia 141
MX - Messico 113
AR - Argentina 111
NL - Olanda 91
FI - Finlandia 87
ZA - Sudafrica 75
IQ - Iraq 67
IE - Irlanda 53
ES - Italia 44
PK - Pakistan 44
AT - Austria 41
JO - Giordania 35
EC - Ecuador 34
KR - Corea 33
VE - Venezuela 33
CO - Colombia 30
MY - Malesia 28
PH - Filippine 28
SA - Arabia Saudita 28
MA - Marocco 27
BE - Belgio 24
AE - Emirati Arabi Uniti 23
CL - Cile 22
TN - Tunisia 22
AU - Australia 18
UZ - Uzbekistan 17
RO - Romania 15
JM - Giamaica 14
DZ - Algeria 13
CH - Svizzera 12
CR - Costa Rica 12
EG - Egitto 12
HN - Honduras 12
NP - Nepal 12
AL - Albania 11
AZ - Azerbaigian 11
ET - Etiopia 11
PE - Perù 11
PT - Portogallo 11
IR - Iran 10
KE - Kenya 10
LT - Lituania 10
BO - Bolivia 9
PY - Paraguay 9
TH - Thailandia 9
KG - Kirghizistan 8
LB - Libano 8
OM - Oman 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
CZ - Repubblica Ceca 7
GE - Georgia 7
IL - Israele 7
PS - Palestinian Territory 7
RS - Serbia 7
DO - Repubblica Dominicana 6
GR - Grecia 6
MD - Moldavia 6
SC - Seychelles 6
UY - Uruguay 6
XK - ???statistics.table.value.countryCode.XK??? 6
BH - Bahrain 5
KZ - Kazakistan 5
NI - Nicaragua 5
SV - El Salvador 5
TW - Taiwan 5
AO - Angola 4
DK - Danimarca 4
KH - Cambogia 4
LV - Lettonia 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BY - Bielorussia 3
CY - Cipro 3
GA - Gabon 3
GT - Guatemala 3
GY - Guiana 3
HR - Croazia 3
QA - Qatar 3
SY - Repubblica araba siriana 3
BB - Barbados 2
Totale 29.048
Salva come PNG Salva come JPEG
Città #
Singapore 1.952
Ashburn 1.693
Fairfield 1.499
Warsaw 1.289
Woodbridge 1.181
San Jose 1.028
Houston 772
Hong Kong 715
Santa Clara 649
Seattle 617
Chandler 551
Jacksonville 499
Wilmington 498
Cambridge 486
Beijing 411
Ann Arbor 380
Izmir 300
Ho Chi Minh City 283
Council Bluffs 282
Dallas 269
Los Angeles 222
Hanoi 184
Princeton 183
Milan 181
Nanjing 170
New York 169
Lauterbourg 154
Tokyo 144
São Paulo 114
The Dalles 110
Jakarta 109
San Diego 108
Boardman 106
Columbus 99
Dearborn 94
Dong Ket 82
London 75
Helsinki 74
Menlo Park 69
Mexico City 69
Moscow 68
Nanchang 68
Toronto 67
Chicago 65
Ferrara 56
Rome 56
Bologna 51
Buffalo 51
Tianjin 47
Orem 46
Hebei 45
Falls Church 42
Shanghai 42
Brooklyn 41
Atlanta 38
Rio de Janeiro 38
Shenyang 38
Phoenix 37
Mountain View 34
Da Nang 32
Haiphong 32
San Francisco 32
Boston 31
Munich 31
Nuremberg 31
Denver 30
Johannesburg 30
Baghdad 29
Montreal 29
Washington 29
Belo Horizonte 26
Changsha 26
Frankfurt am Main 26
Jiaxing 25
Redwood City 25
Stockholm 25
Kunming 24
Biên Hòa 22
Brussels 22
Manchester 22
Norwalk 22
Vienna 22
Naples 21
Brasília 20
Poplar 20
Chennai 19
Curitiba 19
Orange 19
Amsterdam 18
Dhaka 18
Hangzhou 17
Hải Dương 17
Porto Alegre 17
Guangzhou 16
Scottsdale 16
Jinan 15
Philadelphia 15
Seoul 15
Tashkent 15
Amman 14
Totale 19.734
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 547
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 397
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 303
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 297
Development of sentinel node localization and ROLL in breast cancer in Europe 283
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 282
A novel radioguided surgery technique exploiting β- decays 281
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 277
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 270
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 260
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 259
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 253
Early use of abiraterone and radium-223 in metastatic prostate cancer 246
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 243
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 243
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 240
Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening 232
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 231
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 231
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 228
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 228
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 223
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy 222
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 218
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 218
A parathyroid carcinoma within a cold thyroid nodule 214
Radioimmunotherapy in brain tumors 213
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 209
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 209
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 207
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 206
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 206
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 205
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 204
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 199
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 198
[18 f]f-psma-1007 radiolabelling without an on-site cyclotron: A quality issue 198
Yttrium-labelled peptides for therapy of NET 196
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest 195
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 194
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 191
177Lu specific activity influence over DOTATATE radiolabeling: experimental data 190
A delphic consensus assessment: Imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management 188
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 188
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 184
Neuroendocrine tumors 184
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 183
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 181
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 181
Positron emission tomography for the detection of colorectal adenomas 180
68ga-psma-11 pet/ct-guided stereotactic body radiation therapy retreatment in prostate cancer patients with psa failure after salvage radiotherapy 180
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 178
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 178
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 176
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 175
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 174
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 174
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors 174
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 173
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 172
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 172
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 172
Dosimetry for treatment with radiolabelled somatostatin analogues. A review 172
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 172
Financial aspects of sentinel lymph node biopsy in early breast cancer 171
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting 171
Sentinel lymph node biopsy in pregnant patients with breast cancer 170
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 170
Long-term results of PRRT in advanced bronchopulmonary carcinoid 170
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 168
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 168
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 168
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 167
Yttrium-based therapy for neuroendocrine tumors 166
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 166
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 164
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 163
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 163
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 162
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 161
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 161
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 160
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 160
Erratum: Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 158
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 158
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 157
Quantitative accuracy of177Lu SPECT imaging for molecular radiotherapy 157
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 157
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 156
Exploratory Analysis of 18F-3’-deoxy-3’-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer 156
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 154
OXavidin for tissue targeting biotinylated therapeutics 154
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide 154
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review 154
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients 153
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen) 152
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 152
CAR-T cell therapy: A potential new strategy against prostate cancer 151
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy 150
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 150
Totale 19.829
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.661
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.059
Totale 156.720
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.219 0 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/20254.132 58 97 333 157 510 407 151 253 697 608 646 215
2025/202610.951 862 523 1.044 1.089 1.532 610 1.343 599 1.031 1.181 651 486
2026/2027809 341 468 0 0 0 0 0 0 0 0 0 0
Totale 29.636